Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NN-843
- Development stage
- Preclinical
- Lead developer
- NanoNewron
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
NN-843 is a bispecific nanobody heterotrimer developed by NanoNewron for the treatment of Alzheimer's disease. The drug candidate utilizes the proprietary NewroBus platform, which consists of nanobodies targeting the Transferrin Receptor 1 (TfR1) to facilitate transport across the blood-brain barrier (BBB) via receptor-mediated transcytosis. The therapeutic component of the construct is a nanobody designed to neutralize Tumor Necrosis Factor alpha (TNF-α), a pro-inflammatory cytokine that plays a central role in neuroinflammation and the progression of neurodegenerative diseases. By combining the BBB-crossing shuttle with a potent anti-TNF-α inhibitor, NN-843 aims to deliver therapeutic activity directly into the central nervous system to mitigate the neuroinflammatory processes associated with Alzheimer's disease. It is currently in the preclinical stage of development.
- Other names
- NanoNewron-TNF-α-TfR1-bispecific nanobody heterotrimerNewroBus + TNF-α inhibitor
02
Targets
TFRC (Transferrin Receptor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on NN-843.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NN-843.